N.I.H. Director Will Temporarily Run C.D.C. in Leadership Shake-Up

Sheryl Gay Stolberg / nytimes - Dr. Jay Bhattacharya will serve as acting director of the Centers for Disease Control and Prevention until President Trump appoints a permanent director.

AI Summary: Dr. Jay Bhattacharya, currently NIH director, has been appointed acting director of the Centers for Disease Control and Prevention, stepping into leadership amid recent departures. He will oversee CDC operations until a permanent nominee is confirmed, inheriting immediate pandemic and preparedness responsibilities — because who doesn’t love an unexpected federal acting role?

#healthcare #publichealth #governmentpolicy #cdc #vaccinesafety

CDC vaccine committee cancels meeting

3 months / beckershospitalreview / Erica Cerutti

Amid CDC upheaval, key vaccine panel won't convene February meeting

3 months / fiercehealthcare

NIH director named acting CDC chief amid leadership shake-ups

3 months / beckershospitalreview / Ella Jeffries

NIH Director Jay Bhattacharya to take over as temporary CDC chief: media reports

3 months / fiercehealthcare

N.I.H. Director Will Temporarily Run C.D.C. in Leadership Shake-Up

3 months / nytimes / Sheryl Gay Stolberg

F.D.A. Reverses Decision and Agrees to Review Moderna’s Flu Vaccine

Christina Jewett and Rebecca Robbins / nytimes - Moderna said it had held further discussions with regulators and announced that the agency would accept the company’s application for approval of its flu vaccine that uses mRNA technology.

AI Summary: After renewed discussions with the company, the FDA reversed its earlier stance and agreed to accept Moderna’s amended application for an mRNA seasonal influenza vaccine. Regulators will now evaluate the submitted safety and efficacy data to determine whether the shot meets approval standards — a regulatory about-face that will keep flu-watchers and investors awake.

#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment #fda #vaccinesafety

Potential Eylea competitor disappoints; FDA to review Moderna’s flu vaccine; Another rare disease rejection; and more

3 months / endpoints / Max Gelman

FDA's abrupt flip-flop on Moderna's mRNA flu shot highlights growing risks to drug-makers of investing in vaccines

3 months / medicalxpress

What the Health? From KFF Health News: Turnarounds and Shake-Ups

3 months / kffhealthnews

Study shows low vaccination rates among expectant mothers in Norway against COVID-19, influenza

3 months / medicalxpress

FDA reverses course; agrees to review Moderna flu vaccine

3 months / beckershospitalreview / Erica Cerutti

Reversal on Moderna's flu application follows atypical path through FDA